arrow
S

Sang Joon Shin

Asan Medical Center
H指数:46
被引数:9,092

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma

肿瘤特异性但具有免疫抑制性的CD39+CD8+ T细胞在透明细胞肾细胞癌中表现出双重作用

2025-09-160
OAAI
Discovery of a selective dual-specificity tyrosine phosphorylation-regulated kinase 1B inhibitor with anti-adipogenic and anti-diabetic activities

发现一种具有抗脂肪生成和抗糖尿病活性的选择性双特异性酪氨酸磷酸化调控激酶1B抑制剂

2025-07-290
OA
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011
CANCER
IF5.1
2024-10-280
OAAI
EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) plus pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)

EV-302:探索性分析nectin-4表达及对一线恩夫妥单抗 vedotin(EV)联合帕博利珠单抗(P)的应答,在既往未治疗的局部晚期或转移性尿路上皮癌(la/mUC)中

2024-09-015
PRE
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Enfortumab Vedotin和Pembrolizumab在未经治疗的晚期尿路上皮癌中的应用

2024-03-07153
PRE
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
2024-03-017
PRE